Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence Risk Factors at a Tertiary Care Hospital in Nepal

NCT06906861 | Completed

• 1 other identifier: 263(6-11) E2, 080/081
• Study Type: observational
• Target: 284
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to determine the prevalence of epistaxis and identify the associated risk factors among patients receiving oral anticoagulants and antiplatelet at a tertiary care hospital in Nepal. A cross-sectional study was conducted among 284 patients receiving oral anticoagulants at a tertiary care hospital over a one-year period. Data were collected through structured interviews and medical record reviews. The prevalence of epistaxis with corresponding 95% CI was calculated, and risk factors were analyzed using multivariate logistic regression. A receiver operating characteristic (ROC) curve was determined to establish the suitability of the model.

Conditions

Epistaxis

Keywords

Epistaxis, oral anticoagulants, antiplatelet, prevalence, risk factors, warfarin

Outcome Measures

Primary Outcomes (1)

• Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence Risk Factors at a Tertiary Care Hospital in Nepal

  This study aims to determine the prevalence of epistaxis and identify the associated risk factors among patients receiving oral anticoagulants and antiplatelet at a tertiary care hospital in Nepal.

  The study was conducted at the department of emergency and ENT over a one-year period, from November 2023 to October 2024.

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The individuals aged 40 years or older who had been prescribed oral anticoagulants or antiplatelet agents for at least 3 months, admitted at the depart of ENT or Emergency at TUTH were the study population of the study

You may qualify if:

• The study included individuals aged 40 years or older who had been prescribed oral anticoagulants or antiplatelet agents for at least 3 months.

You may not qualify if:

• Patients were excluded if they had a known bleeding disorder unrelated to the use of anticoagulant or antiplatelet medication, a history of coagulopathy or other bleeding disorders (e.g., hemophilia), recent craniofacial or nasal trauma or surgery within the past 6 months, a known history of nasal polyps or other nasal lesions, or if they declined to provide consent.

Sponsors & Collaborators

• Institute of medicine, Maharagjung medical campus: lead

Study Sites (1)

IOM

Kathmandu, Bagmati, +977, Nepal

Location

MeSH Terms

Conditions

Epistaxis

Condition Hierarchy (Ancestors)

Nose Diseases; Respiratory Tract Diseases; Otorhinolaryngologic Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Signs and Symptoms, Respiratory; Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Mr.

Study Record Dates

• First Submitted: March 26, 2025
• First Posted: April 2, 2025
• Study Start: November 1, 2023
• Primary Completion: November 10, 2024
• Study Completion: November 10, 2024
• Last Updated: April 2, 2025

Record last verified: 2025-03

Locations

NE (1)